

PCT

Print Out (Original in Electronic Form)

VIII-2-1	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application Janssen Research & Development, LLC is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-1(iv)		an assignment from DASKALAKIS Nikki to Janssen Research & Development, LLC, dated 17 June 2021 (17.06.2021)
VIII-2-1(iv)		an assignment from GUTTKE Christina Diane to Janssen Research & Development, LLC, dated 17 June 2021 (17.06.2021)
VIII-2-1(iv)		an assignment from FERRANTE Lucille Angela to Janssen Research & Development, LLC, dated 17 June 2021 (17.06.2021)
VIII-2-1(iv)		an assignment from PACKMAN Kathryn Elizabeth to Janssen Research & Development, LLC, dated 17 June 2021 (17.06.2021)
VIII-2-1(iv)		an assignment from PIETSCH Eva Christine to Janssen Research & Development, LLC, dated 17 June 2021 (17.06.2021)
VIII-2-1(iv)		an assignment from BHOGAL Balpreet to Janssen Research & Development, LLC, dated 17 June 2021 (17.06.2021)
VIII-2-1(iv)		an assignment from SUN Yu to Janssen Research & Development, LLC, dated 17 June 2021 (17.06.2021)
VIII-2-1(iv)		an assignment from DASKALAKIS Nikki to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from GUTTKE Christina Diane to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from FERRANTE Lucille Angela to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from PACKMAN Kathryn Elizabeth to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from PIETSCH Eva Christine to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)

PCT

Print Out (Original in Electronic Form)

VIII-2-1(iv)		an assignment from BHOGAL Balpreet to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from SUN Yu to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from DASKALAKIS Nikki to Janssen Research & Development, LLC, dated 11 May 2021 (11.05.2021)
VIII-2-1(iv)		an assignment from GUTTKE Christina Diane to Janssen Research & Development, LLC, dated 11 May 2021 (11.05.2021)
VIII-2-1(iv)		an assignment from FERRANTE Lucille Angela to Janssen Research & Development, LLC, dated 11 May 2021 (11.05.2021)
VIII-2-1(iv)		an assignment from PACKMAN Kathryn Elizabeth to Janssen Research & Development, LLC, dated 11 May 2021 (11.05.2021)
VIII-2-1(iv)		an assignment from PIETSCH Eva Christine to Janssen Research & Development, LLC, dated 11 May 2021 (11.05.2021)
VIII-2-1(iv)		an assignment from DASKALAKIS Nikki to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from GUTTKE Christina Diane to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from FERRANTE Lucille Angela to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from PACKMAN Kathryn Elizabeth to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from PIETSCH Eva Christine to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from BHOGAL Balpreet to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)
VIII-2-1(iv)		an assignment from SUN Yu to Janssen Research & Development, LLC, dated 11 April 2022 (11.04.2022)

PCT

Print Out (Original in Electronic Form)

VIII-2-2	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application JANSSEN PHARMACEUTICA NV is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-2(iv)		an assignment from KWON Min Chul to JANSSEN PHARMACEUTICA NV, dated 17 June 2021 (17.06.2021)
VIII-2-2(iv)		an assignment from PHILIPPAR Ulrike to JANSSEN PHARMACEUTICA NV, dated 17 June 2021 (17.06.2021)
VIII-2-2(iv)		an assignment from VERHULST Tinne Ann J to JANSSEN PHARMACEUTICA NV, dated 17 June 2021 (17.06.2021)
VIII-2-2(iv)		an assignment from ALI-AHMED Sumia to JANSSEN PHARMACEUTICA NV, dated 17 June 2021 (17.06.2021)
VIII-2-2(iv)		an assignment from THURING Johannes Wilhelmus J. to JANSSEN PHARMACEUTICA NV, dated 17 June 2021 (17.06.2021)
VIII-2-2(iv)		an assignment from DARVILLE Nicolas Freddy J to JANSSEN PHARMACEUTICA NV, dated 17 June 2021 (17.06.2021)
VIII-2-2(iv)		an assignment from PANDE Vineet to JANSSEN PHARMACEUTICA NV, dated 17 June 2021 (17.06.2021)
VIII-2-2(iv)		an assignment from KWON Min Chul to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from PHILIPPAR Ulrike to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from VERHULST Tinne Ann J to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from ALI-AHMED Sumia to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from THURING Johannes Wilhelmus J. to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)

PCT

Print Out (Original in Electronic Form)

VIII-2-2(iv)		an assignment from DARVILLE Nicolas Freddy J to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from PANDE Vineet to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from KWON Min Chul to JANSSEN PHARMACEUTICA NV, dated 11 May 2021 (11.05.2021)
VIII-2-2(iv)		an assignment from PHILIPPAR Ulrike to JANSSEN PHARMACEUTICA NV, dated 11 May 2021 (11.05.2021)
VIII-2-2(iv)		an assignment from VERHULST Tinne Ann J to JANSSEN PHARMACEUTICA NV, dated 11 May 2021 (11.05.2021)
VIII-2-2(iv)		an assignment from THURING Johannes Wilhelmus J. to JANSSEN PHARMACEUTICA NV, dated 11 May 2021 (11.05.2021)
VIII-2-2(iv)		an assignment from DARVILLE Nicolas Freddy J to JANSSEN PHARMACEUTICA NV, dated 11 May 2021 (11.05.2021)
VIII-2-2(iv)		an assignment from PANDE Vineet to JANSSEN PHARMACEUTICA NV, dated 11 May 2021 (11.05.2021)
VIII-2-2(iv)		an assignment from KWON Min Chul to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from PHILIPPAR Ulrike to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from VERHULST Tinne Ann J to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from THURING Johannes Wilhelmus J. to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from DARVILLE Nicolas Freddy J to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-2(iv)		an assignment from PANDE Vineet to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)

PCT

Print Out (Original in Electronic Form)

VIII-2-3	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-3(iv)		an assignment from CAI Wei to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 17 June 2021 (17.06.2021)
VIII-2-3(iv)		an assignment from DAI Xuedong to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 17 June 2021 (17.06.2021)
VIII-2-3(iv)		an assignment from LIU Yingtao to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 17 June 2021 (17.06.2021)
VIII-2-3(iv)		an assignment from LIU Lianzhu to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 17 June 2021 (17.06.2021)
VIII-2-3(iv)		an assignment from XU Yanping to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 17 June 2021 (17.06.2021)
VIII-2-3(iv)		an assignment from FU Liqiang to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 17 June 2021 (17.06.2021)
VIII-2-3(iv)		an assignment from LI Ming to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 17 June 2021 (17.06.2021)
VIII-2-3(iv)		an assignment from FANG Lichao to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 17 June 2021 (17.06.2021)
VIII-2-3(iv)		an assignment from DENG Xiangjun to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 17 June 2021 (17.06.2021)
VIII-2-3(iv)		an assignment from NG Alicia Tee Fuay to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 17 June 2021 (17.06.2021)
VIII-2-3(iv)		an assignment from CAI Wei to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from DAI Xuedong to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)

PCT

Print Out (Original in Electronic Form)

VIII-2-3(iv)		an assignment from DENG Xiangjun to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from FANG Lichao to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from FU Liqiang to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from LI Ming to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from LIU Lianzhu to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from LIU Yingtao to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from XU Yanping to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from NG Alicia Tee Fuay to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from CAI Wei to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 May 2021 (11.05.2021)
VIII-2-3(iv)		an assignment from DAI Xuedong to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 May 2021 (11.05.2021)
VIII-2-3(iv)		an assignment from LIU Yingtao to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 May 2021 (11.05.2021)
VIII-2-3(iv)		an assignment from LIU Lianzhu to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 May 2021 (11.05.2021)
VIII-2-3(iv)		an assignment from XU Yanping to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 May 2021 (11.05.2021)
VIII-2-3(iv)		an assignment from FU Liqiang to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 May 2021 (11.05.2021)

PCT

Print Out (Original in Electronic Form)

VIII-2-3(iv)		an assignment from LI Ming to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 May 2021 (11.05.2021)
VIII-2-3(iv)		an assignment from FANG Lichao to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 May 2021 (11.05.2021)
VIII-2-3(iv)		an assignment from DENG Xiangjun to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 May 2021 (11.05.2021)
VIII-2-3(iv)		an assignment from NG Alicia Tee Fuay to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 May 2021 (11.05.2021)
VIII-2-3(iv)		an assignment from CAI Wei to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from DAI Xuedong to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from DENG Xiangjun to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from FANG Lichao to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from FU Liqiang to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from LI Ming to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from LIU Lianzhu to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from LIU Yingtao to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from XU Yanping to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)
VIII-2-3(iv)		an assignment from NG Alicia Tee Fuay to JOHNSON & JOHNSON (CHINA) INVESTMENT LTD., dated 11 April 2022 (11.04.2022)

PCT

Print Out (Original in Electronic Form)

VIII-2-4	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application J ansssen-Cilag is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-4(iv)		an assignment from QUEROLLE Olivier Alexis Georges to Janssen-Cilag, dated 17 June 2021 (17.06.2021)
VIII-2-4(iv)		an assignment from QUEROLLE Olivier Alexis Georges to Janssen-Cilag, dated 11 April 2022 (11.04.2022)
VIII-2-4(iv)		an assignment from QUEROLLE Olivier Alexis Georges to Janssen-Cilag, dated 11 May 2021 (11.05.2021)
VIII-2-4(iv)		an assignment from QUEROLLE Olivier Alexis Georges to Janssen-Cilag, dated 11 April 2022 (11.04.2022)

PCT

Print Out (Original in Electronic Form)

VIII-2-5	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application JANSSEN PHARMACEUTICA NV is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-5(iv)		an assignment from JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. to JANSSEN PHARMACEUTICA NV, dated 17 June 2021 (17.06.2021)
VIII-2-5(iv)		an assignment from Janssen-Cilag to JANSSEN PHARMACEUTICA NV, dated 17 June 2021 (17.06.2021)
VIII-2-5(iv)		an assignment from Janssen Research & Development, LLC to JANSSEN PHARMACEUTICA NV, dated 17 June 2021 (17.06.2021)
VIII-2-5(iv)		an assignment from Janssen-Cilag to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-5(iv)		an assignment from JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-5(iv)		an assignment from Janssen Research & Development, LLC to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-5(iv)		an assignment from Janssen Research & Development, LLC to JANSSEN PHARMACEUTICA NV, dated 11 May 2021 (11.05.2021)
VIII-2-5(iv)		an assignment from Janssen-Cilag to JANSSEN PHARMACEUTICA NV, dated 11 May 2021 (11.05.2021)
VIII-2-5(iv)		an assignment from JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. to JANSSEN PHARMACEUTICA NV, dated 11 May 2021 (11.05.2021)
VIII-2-5(iv)		an assignment from Janssen Research & Development, LLC to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-5(iv)		an assignment from Janssen-Cilag to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)
VIII-2-5(iv)		an assignment from JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. to JANSSEN PHARMACEUTICA NV, dated 11 April 2022 (11.04.2022)